December 6, 2018
Collaboration helps physicians spend less time on data entry and more time on patient care
LAS COLINAS, TEXAS and SAN FRANCISCO, December 6, 2018—McKesson Corporation, which has been investing in technologies and services that create more efficiencies for healthcare providers, and Augmedix, a technology-enabled service for health systems and providers, announced the expansion of an innovative pilot between the Augmedix electronic health record (EHR) documentation platform and the McKesson oncology EHR iKnowMedSM.Read More
November 30, 2018
Top researchers will present abstracts on latest clinical research advancing cancer treatment options
THE WOODLANDS, TEXAS, November 30, 2018— During the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, principal investigators from The US Oncology Network and US Oncology Research will demonstrate detailed results from 18 studies (two orals, 15 poster presentations and one late-breaking abstract) covering topics including multiple myeloma, plasma cell disorders, lymphoid malignancies, follicular lymphoma, non-Hodgkin lymphoma and more. The ASH Annual Meeting, a leading scientific event in malignant and non-malignant hematology, will be held December 1-4 in San Diego.Read More
October 8, 2018
More than 200 leading cancer researchers gathered to discuss the future of cancer care
THE WOODLANDS, TEXAS, October 8, 2018—US Oncology Research recently held its 17th Annual Science Forum (the Forum) in Denver, bringing together more than 200 leading research physicians and their clinical teams. This year’s agenda included a focus on leading-edge clinical and technological topics, including artificial intelligence, the immunologic bank and new gene treatments like CAR-T cell therapies.
“This meeting brings outstanding new science to help our patients now,” said Daniel Von Hoff, MD, FACP, chief scientific officer, US Oncology Research. “This science will allow earlier diagnosis via artificial intelligence, introduction of new therapeutics with unique mechanisms of action, the maximum harnessing of a person’s immune system to prevent or eliminate cancer, and gene therapy to likely cure diseases we never dreamed we could change.”Read More
October 4, 2018
Affiliated practices to benefit from high positive payment adjustment
THE WOODLANDS, TEXAS, October 4, 2018— The US Oncology Network (The Network) today announced results of the 2017 Merit-based Incentive Payment System (MIPS) for its affiliated practices. Based on the successful implementation of quality improvement, adoption and performance in the first year of MIPS, practices in The Network will receive an average positive payment adjustment of 1.90%*—close to the maximum allowable adjustment of 2.02%*. In addition, 99% of physicians in The Network were in the top tier of performers.
Launched in 2017, MIPS is a bi-partisan government-mandated program that aims to reduce healthcare costs and improve quality. The 2017 results were released by the Centers for Medicare and Medicaid Services (CMS) on June 29, 2018. A clinician’s performance in 2017 will impact their Medicare reimbursement in 2019.Read More
August 23, 2018
Dataset of up to 10,000 full genome profiles matched with complete clinical data will provide representative resource for breast cancer research
THE WOODLANDS, TEXAS, U.S., IRVINE, CALIF., U.S. and AMSTERDAM, NETHERLANDS (August 23, 2018) – Agendia, Inc., a world leader in precision oncology, announced today that US Oncology Research, one of the nation’s largest research networks dedicated to bringing cutting-edge treatment options to cancer patients and consisting of more than 150 research sites and over 1,000 investigators, has joined Agendia’s FLEX breast cancer registry study. FLEX is a large-scale, prospective, observational breast cancer study that links full genome profiling, including Agendia’s MammaPrint® risk of recurrence and BluePrint® molecular subtyping tests, with complete clinical data to create a comprehensive patient database with the potential to identify new gene associations with prognostic and/or predictive value in breast cancer.Read More
August 15, 2018
Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer
US Oncology Research will open 10 clinical trial sites, enrolling patients in Novocure’s PANOVA-3 trial to test the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancerRead More
August 6, 2018
More patients in suburban Chicago will benefit from the combined expertise and resources
Chicago, Illinois (August 6, 2018) – Illinois Cancer Specialists (ICS), an affiliate of The US Oncology Network (The Network), announced today that Progressive Care has joined its practice. The combined practice will continue to offer comprehensive, state-of-the-art cancer care in its nine convenient, patient-friendly community settings throughout suburban Chicago. ICS has been a part of The US Oncology Network, one of the nation’s largest networks of integrated community-based oncology practices, for several years.
“The Network will benefit greatly from the addition of these experienced oncology care providers,” said Marcus Neubauer, M.D., chief medical officer. “I am looking forward to collaborating with them as part of our larger organization in the Chicago area.”Read More
July 17, 2018
Medical oncologist is appointed to spearhead The Network’s significant medical programs and collaborative, integrated approach to cancer care
The Woodlands, Texas (July 17, 2018) —The US Oncology Network (The Network) announced the appointment of Marcus Neubauer, M.D., as its chief medical officer, building on its mission of delivering a comprehensive approach to cancer care. Michael Seiden, M.D., Ph.D. will continue to lead The Network as its president.
Dr. Neubauer has been a practicing medical oncologist for over 20 years, serving previously as a physician and leader in our Kansas City practice. For the past five years he has served as the vice president and medical director for payer, clinical services, and value-based care, working with over 1,400 community oncologists across the country. He is a recognized leader in innovation in clinical pathways, value-based care and contracting and the Center for Medicare and Medicaid Innovation’s (CMMI®) Oncology Care Model.Read More
July 9, 2018
Renowned breast surgeon appointed to spearhead The Network’s surgical programs and collaborative, integrated approach to cancer care
The Woodlands, Texas (July 9, 2018) —The US Oncology Network (The Network) announced the appointment of Loren Rourke, M.D., M.H.C.M., as its chief surgical officer, a new role created to support and enhance the surgical community within The Network, fortifying its mission of delivering comprehensive approach to cancer care.
Dr. Rourke brings more than 15 years of surgical experience to The US Oncology Network – experience that includes numerous academic appointments, committees, honors, awards and publications. Most recently, she served as regional breast program director at Houston Methodist. Previously, she held such leadership positions as medical director for the Maine Medical Center Cancer Institute Breast Center (Scarborough, ME) and surgical director of St. Luke’s Woodlands breast program.Read More
May 30, 2018
Expansive clinical research and real-world evidence data to be presented on prostate cancer, genome sequencing, melanoma, bladder cancer, metastatic breast cancer and more
The Woodlands, Texas (May 30, 2018) – McKesson Specialty Health announced today that oncologists from The US Oncology Network (The Network) and US Oncology Research will showcase detailed findings from 43 studies during the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), held June 1–5, 2018, in Chicago with more than 32,000 oncology professionals in attendance. The study abstracts accepted for presentation represent substantial contributions made by community oncologists towards the understanding and advancement of cancer care.Read More
May 16, 2018
Study Wins the 2018 Clinical and Research Excellence (CARE) Award for Best in Health Economics and Outcomes
The Woodlands, Texas (May 16, 2018) — A powerful, real-world evidence study designed by McKesson Specialty Health for its biopharma partner played a key role in the Food and Drug Administration’s (FDA) approval for first-line indication for a rare disease. Recently “Merkel Cell Carcinoma Observational Study for Historic Comparison” received the 2018 Clinical and Research Excellence (CARE) Award for Best in Health Economics and Outcomes Research, recognizing how data research supports true innovation in oncology care.
The award acknowledges excellence in health economics and outcomes research (HEOR), a strategic focus for the company, and was announced at an award ceremony with organizers Pharma Intelligence, biopharma companies, researchers, and providers last month in Boston.Read More
May 7, 2018
Industry Recognition Highlights Texas Oncology’s Integrated Pharmacy Approach to Attain Better Patient Outcomes and Lower Costs
DALLAS (May 7, 2018) — Texas Oncology, a practice in The US Oncology Network (The Network), received a 2018 Excellence Award from Pharmacy Benefit Management Institute® (PBMI) for its Medically Integrated Pharmacy Management (MIPM) approach to achieve better results in cancer care. The MIPM model includes a team of board-certified oncologists, as well as other healthcare professionals, to deliver patient-focused solutions that drive industry-leading outcomes and contain costs.Read More
March 12, 2018
Renowned breast surgeon joins practice with more than two decades of experience, expanding the service offering to more patients
Fairfax, Va. (March 12, 2018) —Virginia Cancer Specialists (VCS) announced that Hernan Vargas, MD, has joined the practice. VCS, a practice in The US Oncology Network, is a premier cancer care and research center in Northern Virginia with more than 40 years of service to patients.Read More
January 18, 2018
Practice increases clinical trial and advanced treatment options while gaining access to resources that improve operational efficiencies
Philadelphia, Pa. (January 18, 2018) – Consultants in Medical Oncology and Hematology (CMOH), a premier provider of comprehensive medical oncology services throughout the Philadelphia region for nearly 30 years and a national leader in the development of patient and physician-focused value-based cancer care delivery models, has joined The US Oncology Network (The Network). The Network is the largest organization of its kind comprised of community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care.Read More
December 4, 2017
19 abstracts on clinical research conducted by top affiliated investigators are scheduled for presentation
The Woodlands, Texas (December 4, 2017) – At the 59th American Society of Hematology Annual Meeting and Exposition (ASH), leading investigators from The US Oncology Network and US Oncology Research will showcase detailed findings from 19 studies (four orals, 14 poster presentations and one e-publication) covering topics such as multiple myeloma, chronic lymphocytic leukemia, myeloproliferative neoplasms and more. The 59th ASH Annual Meeting, a premier scientific event in malignant and non-malignant hematology, will be held December 9-12 in Atlanta.Read More
November 28, 2017
Dr. Akbari, a pioneer in breast cancer surgery, brings new line of treatment services to the clinic
Fairfax, Va. (November 28, 2017) —Virginia Cancer Specialists (VCS) announced that Stephanie Akbari, MD, FACS, has joined the practice. VCS, a practice in The US Oncology Network, is a premier cancer care and research center in Northern Virginia with more than 40 years of service to patients.Read More
September 19, 2017
Mobile, Ala. (September 19, 2017) - Southern Cancer Center (SCC), a premier oncology clinic in Alabama and a practice in The US Oncology Network, is the first site in the world to open enrollment for a new clinical trial for newly diagnosed kidney cancer patients.
This phase 3 clinical trial will look at various investigational combination therapies including an immune checkpoint inhibitor. This is an important trial to gain information on previously untreated advanced or metastatic renal cell carcinoma (RCC).Read More